Birdwatch Archive - Rating Details

Birdwatch Note Rating

2023-07-09 12:24:16 UTC - NOT_HELPFUL

Rated by Participant: 11D62E08D377313EA85B58017F200FEB0CB4EC37C49328FF9D2C48E8DA6B6149
Participant Details

Original Note:

The Phase 3 LUCIDITY trial for hydromethylthionine mesylate (HMTM) failed to meet its endpoint as reported on Medscape. Additional trials are underway. The LUCIDITY trial did have encouraging results that TauRx Pharmaceuticals are promoting through PR releases. https://www.prnewswire.com/in/news-releases/lucidity-phase-3-topline-data-presented-at-ctad-for-hmtm--the-only-oral-anti-tau-therapy-in-late-stage-development-301690475.html https://www.medscape.com/viewarticle/984863 https://archive.is/awWDp

All Note Details

Original Tweet

All Information

noteId - 1677803233077522432
participantId -
raterParticipantId - 11D62E08D377313EA85B58017F200FEB0CB4EC37C49328FF9D2C48E8DA6B6149
createdAtMillis - 1688905456790
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - NOT_HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 0
helpfulEmpathetic - 0
helpfulGoodSources - 0
helpfulUniqueContext - 0
helpfulAddressesClaim - 0
helpfulImportantContext - 0
helpfulUnbiasedLanguage - 0
notHelpfulOther - 0
notHelpfulIncorrect - 1
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 0
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 1
ratingsId - 167780323307752243211D62E08D377313EA85B58017F200FEB0CB4EC37C49328FF9D2C48E8DA6B6149